SCHEMBL34464816

SCHEMBL34464816

CCNNC(=O)c1ccc(-c2ccnc(N3CCC4(CC3)COC4)n2)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HDAC3 O15379 4/20 0.41
▸ HDAC8 Q9BY41 2/20 0.41
▸ JAK2 O60674 10/20 0.41
▸ JAK3 P52333 9/20 0.41
▸ JAK1 P23458 5/20 0.41
▸ HDAC1 Q13547 4/20 0.41
▸ TYK2 P29597 2/20 0.41
▸ BMPR1B O00238 1/20 0.41
▸ PLK4 O00444 1/20 0.41
▸ CIT O14578 1/20 0.41
▸ GAK O14976 1/20 0.41
▸ OPA1 O60313 1/20 0.41
▸ ROCK2 O75116 1/20 0.41
▸ STK16 O75716 1/20 0.41
▸ PRKD3 O94806 1/20 0.41
▸ CSNK2A2 P19784 1/20 0.41
▸ CDK2 P24941 1/20 0.41
▸ MARK3 P27448 1/20 0.41
▸ BMPR1A P36894 1/20 0.41
▸ TGFBR1 P36897 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL34464825 0.89 PIK3CA (0.39) JAK2JAK3JAK1HDAC1TYK2
SCHEMBL34464803 0.87 PIK3CA (0.52) HDAC3HDAC8JAK2JAK3JAK1
SCHEMBL34464785 0.86 HDAC1 (0.52) HDAC3HDAC8JAK2JAK3JAK1
SCHEMBL34464778 0.83 HDAC3 (0.40) HDAC3HDAC8JAK2JAK3JAK1
SCHEMBL34464870 0.83 CYP3A4 (0.45) JAK2HCAR2KDM4EPIK3CADKK1
SCHEMBL34464755 0.79 TBK1 (0.36) HDAC3HDAC8JAK2JAK3JAK1
SCHEMBL34464880 0.73 SMO (0.34) JAK2JAK3JAK1PIK3CA
SCHEMBL34464784 0.72 HDAC1 (0.49) HDAC3HDAC8JAK2JAK3JAK1
SCHEMBL34464822 0.72 JAK2 (0.50) HDAC3HDAC8JAK2JAK3JAK1
SCHEMBL34464752 0.69 CA2 (0.43) NEK3CAMK2DHCAR2KDM4EPIK3CA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260109690-A1 HDAC6 INHIBITORS AND METHOD OF THEIR USE BAERENKRAFT THERAPEUTICS LLC (US) 2026-04-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260109690-A1 HDAC6 INHIBITORS AND METHOD OF THEIR USE HDAC6, HDAC3, HDAC1 HDAC3 2/4885HDAC8 6/4885JAK2 2639/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback